Lenalidomide to prevent IgG4-related disease relapse
Treatments studied
Part of Immune system & allergy clinical trials.
This trial tests if lenalidomide, taken as a pill, can help prevent IgG4-related disease from coming back (relapsing) in people who are already in remission on low-dose steroids.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have been diagnosed with IgG4-related disease (using standard criteria).
- Your disease has been in remission (no active symptoms) on steroids for at least the past year.
- You have been on a stable low dose of prednisone (or equivalent) of 7.5 mg per day or less for at least 6 months.
- You have not had any disease flare-ups in the last 12 months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a medication called rilzabrutinib to see if it can safely control IgG4-related disease (a condition causing inflammation in various organs) better than a placebo. It may help you reduce or stop your current steroid treatment.
This trial tests if inebilizumab is safe and works well for children with IgG4-related disease (a condition causing swelling in various organs). It may be an option if your child needs treatment beyond steroids.
This study looks at a specific immune signal (C5a/C5aR1) in IgG4-related disease to see if blocking that signal could be a future treatment. It compares blood samples from people with active disease, people in remission, and healthy volunteers.
This study tests a drug called lenalidomide to see if it can help control active IgG4-related disease, a condition that causes inflammation and swelling in organs. The drug is taken by mouth, and the study compares it to a placebo (a pill with no medicine).
This trial tests a short course of steroids combined with mycophenolate mofetil (MMF) for people with active IgG4-related disease who have not been treated before or whose disease came back after stopping treatment. The goal is to see if this combination helps control the disease better.
This trial is studying treatment plans for people with IgG4-related disease that affects a surface (superficial) organ area. It focuses on people who are newly diagnosed or have come back and who need to start or continue steroid medicine at a low dose.
Hear when a new Immunoglobulin G4-Related Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.